003060 — Aprogen Biologics Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩103bn
- KR₩274bn
- KR₩87bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -3,467 | 18,918 | 9,151 | 5,584 | -115,330 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 2,629 | -18,500 | -10,299 | -8,265 | 66,047 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -55 | 5,936 | -6,952 | 26,205 | -5,508 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 714 | 8,088 | -6,227 | 25,728 | -33,651 |
Capital Expenditures | -2,421 | -1,421 | -1,442 | -1,545 | -28,396 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -68,048 | -193,847 | -21,714 | -51,456 | -66,810 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -70,469 | -195,268 | -23,156 | -53,001 | -95,206 |
Financing Cash Flow Items | -1,609 | -13,262 | -0.955 | -455 | 2,943 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 78,443 | 221,704 | -350 | 15,782 | 115,289 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 8,666 | 34,499 | -29,722 | -11,465 | -13,555 |